#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16990	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2510	827.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1574	1574	C	1080	C	1080	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29008	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4176	867.3	0	.	n	.	0	T695C	SNP	695	695	T	1286	1286	C	1082	C,T,G	1078,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29008	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4176	867.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1928	1928	A	1192	A	1192	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29008	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4176	867.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2562	2562	C	1050	C,T,G	1048,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29008	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4176	867.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2636	2636	A	920	A,G	919,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29008	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4176	867.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3188	3188	C	1034	C,A,G	1032,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	27	2358	folP	855	855	100.0	folP.l15.c17.ctg.1	1872	156.1	1	SNP	p	R229S	0	.	.	685	687	CGC	1163	1165	CGC	247;246;249	C,G,A;G;C,T	244,2,1;246;248,1	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5732	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3909	183.0	1	SNP	p	S91F	0	.	.	271	273	TCC	862	864	TCC	195;194;193	T;C;C,A	195;194;192,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5732	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3909	183.0	1	SNP	p	D95G	0	.	.	283	285	GAC	874	876	GAC	202;202;203	G,T;A,G;C,T	201,1;201,1;202,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5732	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3909	183.0	1	SNP	p	D95N	0	.	.	283	285	GAC	874	876	GAC	202;202;203	G,T;A,G;C,T	201,1;201,1;202,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	2220	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1852	149.5	1	SNP	p	G45D	1	.	.	133	135	GAC	752	754	GAC	269;272;271	G,A;A,G;C,A	268,1;271,1;270,1	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1208	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1659	91.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	5630	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3428	204.6	1	SNP	p	D86N	0	.	.	256	258	GAC	857	859	GAC	249;249;247	G;A;C,G	249;249;246,1	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	5630	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3428	204.6	1	SNP	p	S88P	0	.	.	262	264	TCC	863	865	TCC	246;249;247	T;C;C,A	246;248;245,1	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4856	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3089	195.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1752	1754	GGC	247;242;239	G,T;G;C	246,1;242;239	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4440	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3087	179.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1610	1612	GCA	295;294;296	G;C;A	295;294;296	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4440	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3087	179.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1613	1615	ATC	297;297;296	A;T,C;C,T	297;296,1;295,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4440	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3087	179.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1625	1627	GTG	281;279;281	G,T;T,A;G	280,1;278,1;281	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4440	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3087	179.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1625	1627	GTG	281;279;281	G,T;T,A;G	280,1;278,1;281	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4440	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3087	179.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2129	2131	ACC	224;225;224	A,G;C;C	223,1;225;224	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4440	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3087	179.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2183	2185	GCG	246;245;245	G;C;G,C	246;245;244,1	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4440	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3087	179.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2183	2185	GCG	246;245;245	G;C;G,C	246;245;244,1	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4440	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3087	179.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2306	2308	GGC	245;244;243	G;G;C	245;244;243	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4440	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3087	179.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2315	2317	GGC	246;246;246	G;G;C	246;246;246	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4440	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3087	179.6	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2333	2335	CTG	259;261;261	C;T;G	259;261;261	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	6410	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3630	220.3	1	SNP	p	L421P	1	L421P	NONSYN	1261	1263	CTG	1915	1917	CCG	258;257;258	C,G;C;G,A	257,1;257;257,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2722	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2332	145.6	0	.	p	.	0	S22G	NONSYN	64	66	AGC	653	655	GGC	198;196;193	G,A;G,A;C	197,1;195,1;193	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2722	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2332	145.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	835	835	C	197	C,A	196,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3396	porB1b	1047	1047	98.47	porB1b.l6.c4.ctg.1	2289	185.0	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	1036	1038	AAG	293;291;291	A;A;G	293;291;291	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3396	porB1b	1047	1047	98.47	porB1b.l6.c4.ctg.1	2289	185.0	0	.	p	.	0	D121G	NONSYN	361	363	GAC	1039	1041	GGC	293;291;291	G;G;C	293;291;290	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3396	porB1b	1047	1047	98.47	porB1b.l6.c4.ctg.1	2289	185.0	0	.	p	.	0	G140R	NONSYN	418	420	GGA	1096	1098	AGA	286;289;290	A,G;G;A	284,2;289;290	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3396	porB1b	1047	1047	98.47	porB1b.l6.c4.ctg.1	2289	185.0	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	1105	1107	CAA	293;292;293	C,A;A;A,C	291,2;292;292,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3396	porB1b	1047	1047	98.47	porB1b.l6.c4.ctg.1	2289	185.0	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1312	1314	GAT	281;286;285	G;A;T	281;286;285	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3396	porB1b	1047	1047	98.47	porB1b.l6.c4.ctg.1	2289	185.0	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1315	1317	GGT	288;288;290	G;G;T	288;288;290	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3396	porB1b	1047	1047	98.47	porB1b.l6.c4.ctg.1	2289	185.0	0	.	p	.	0	Q214H	NONSYN	640	642	CAA	1318	1320	CAT	289;291;289	C;A;T	289;291;289	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3396	porB1b	1047	1047	98.47	porB1b.l6.c4.ctg.1	2289	185.0	0	.	p	.	0	V215A	NONSYN	643	645	GTT	1321	1323	GCT	292;293;297	G,A;C;T	291,1;293;297	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3396	porB1b	1047	1047	98.47	porB1b.l6.c4.ctg.1	2289	185.0	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1447	1449	ACG	267;263;259	A;C,G;G,A	267;262,1;258,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3396	porB1b	1047	1047	98.47	porB1b.l6.c4.ctg.1	2289	185.0	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1453	1455	GTT	255;251;254	G,A,C;T,C;T,C	252,2,1;250,1;253,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3396	porB1b	1047	1047	98.47	porB1b.l6.c4.ctg.1	2289	185.0	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1567	1569	AAC	273;277;278	A;A,T;C	273;276,1;278	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11236	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5401	259.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1760	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1619	135.7	1	SNP	p	V57M	1	.	.	169	171	ATG	767	769	ATG	313;316;314	A;T;G,C	313;316;313,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
